Sunday, April 13 | 1:45–2:45 p.m.
Aleksandar Rajkovic, M.D., Ph.D., University of California San Francisco
This presentation will explore the development and clinical integration of a preemptive pharmacogenomics (PGx) testing program at UCSF Health. Attendees will gain insights into the program’s design, including the creation of electronic clinical decision support (CDS) for 56 medications and 15 genes, the role of multidisciplinary collaboration, and strategies to overcome bioinformatics and non-bioinformatics challenges. Key outcomes and lessons from UCSF’s approach to optimizing medication management through personalized medicine will be discussed.
After attending this presentation, participants should be able to:
• Describe the process of developing and implementing a preemptive pharmacogenomics testing program integrated with an electronic health record (EHR) system.
• Identify the challenges and solutions in integrating clinical decision support tools for pharmacogenomics into clinical workflows.
• Evaluate the impact of pharmacogenomics testing on clinical decision-making, patient outcomes, and medication safety.
Yassmine Akkari, Ph.D., Nationwide Children's Hospital & The Ohio State University
The unified goal of NCI’s Molecular Characterization Initiative in childhood cancers is to combine DNA analysis in terms of sequence variation, mutational signature, and copy number, RNA analysis for structural variant detection, as well as DNA methylation arrays to inform the epigenetics of these tumors. The information will aid in refining tumor diagnoses, defining therapeutic targets and predicting treatment toxicity with the goal of enabling precision medicine and improved patient outcomes. In addition, information from molecular profiling can inform family screening and surveillance from germline testing results. We will discuss participation in MCI as well as laboratory testing workflows and lessons learned.
After attending this presentation, participants should be able to:
• State the objectives of NCI’s Molecular Characterization Initiative (MCI).
• Summarize the laboratory workflow and result interpretation for MCI samples.
• Discuss interesting cases and lessons learned.
The program includes sessions, networking opportunities, industry spotlights and more.
View program
